BioNTech SE · NASDAQ:BNTX
BioNTech — Shareholder Meeting (May 2026)
22 slides from BioNTech's shareholder meeting presentation, May 15, 2026
Slide 1: Annual General Meeting 15 May 2026
Annual General Meeting 15 May 2026, 14:00 CEST Exhibit 99.2
Slide 2: Management Report
Operations Development 2025 & Q1 2026 and Outlook 2026 Prof. Dr. Uğur Şahin, Co-Founder & Chief Executive Officer Financial Development 2025 & Q1 2026 and Financial Outlook 2026 Ramón Zapata, Chief Financial Officer 1 2 2 Management Report
Slide 3: Operations Development 2025 & Q1 2026 and Outlook 2026
Operations Development 2025 & Q1 2026 and Outlook 2026 Prof. Dr. Uğur Şahin, Co-Founder & Chief Executive Officer 1 3
Slide 4: Forward-looking statements
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech’s expected revenues and net profit/(loss) related to sales of BioNTech’s COVID-19 vaccine, refe
Slide 5: Continuing to Execute on BioNTech's Strategy
COVID-19 Vaccine Global Impact Addressing Oncology Unmet Medical Need Focused Infectious Disease Innovation 5 Billion vaccine doses distributed1 >25 Ongoing Phase 2 & Phase 3 trials2 17 Clinical programs3 7 High unmet need clinical programs4 Continuing to Execute on BioNTech’s Strategy 5 1. Includes
Slide 6: 2025 Achievements: Strong Performance and Pipeline Momentum
2025 Achievements: Strong Performance and Pipeline Momentum 6 1. Over 50%, including Italy, Spain, France, Germany, USA, Japan, Australia. COVID-19 Market Leadership1 Advanced Key Oncology Programs Executed Key Strategic Deals Strengthened Financial Position
Slide 7: Strategic Oncology Multi-Modal Immunotherapy Approach
Strategic Oncology Multi-Modal Immunotherapy Approach 7 1. Synergistic potential Space for curative approaches Immunomodulators Targeted therapies Synergy1Synergy1 Synergy1 mRNA cancer immunotherapies • Precise and potent modalities for fast onset tumor reduction • ADC as potential “augmenters” of i
Slide 8: Innovative BMS Partnership Structured to Accelerate Pumitamig's Potential
Innovative BMS Partnership Structured to Accelerate and Maximize Pumitamig’s Potential 8 Maximizing potential of next-generation PD-L1xVEGF-A bispecific antibody, pumitamig, with global co-development and co-commercialization BMS partnership Seven global registrational trials for pumitamig ongoing 5
Slide 9: BioNTech Key Tumor Focus Areas to Address Significant Unmet Medical Needs
BioNTech Key Tumor Focus Areas to Address Significant Unmet Medical Needs 9 1. Partnered with Bristol Myers Squibb Leveraging novel combinations to maximize pipeline potential and elevate solid tumor treatment outcomes Lung Breast Genitourinary Gastrointestinal Gynecologic Additional Tumors Pumitami
Slide 10: Building a Multi-Product Company by 2030
Building a Multi-Product Company by 2030 Targeting 17+ Late-Stage/Pivotal Trial Readouts Through 2030+ Informing Multiple Launch Opportunities 10 1. Expected data readouts may be from interim or final analyses and are event-driven, and in some cases may not translate into commercial launches; Partne
Slide 11: Our Mission and Vision
Our Mission We are committed to improving the health of people worldwide with our fundamental research and work in the development of immunotherapies. Our Vision We aspire to harness the power of the immune system to develop novel therapies against cancer, infectious diseases and other severe diseas
Slide 12: Financial Development 2025 & Q1 2026 and Financial Outlook 2026
Financial Development 2025 & Q1 2026 and Financial Outlook 2026 Ramón Zapata, Chief Financial Officer 2 12
Slide 13: Full Year 2025 Financial Results Compared to Guidance
Full Year 2025 Financial Results Compared to Guidance 13 1. All numbers have been rounded. More information can be found in BioNTech’s Report on Form 20-F for the year ended December 31, 2025, filed on March 10, 2026, as amended, which is available at www.sec.gov. In € millions FY 2025 IFRS Results1
Slide 14: First Quarter 2026 Unaudited Financial Results Highlights
First Quarter 2026 Unaudited Financial Results Highlights1 14 1. All numbers have been rounded. 2. In addition to BioNTech’s results determined in accordance with International Financial Reporting Standards (“IFRS”), or IFRS Accounting Standards, or IFRS results, BioNTech reports certain adjusted, n
Slide 15: Reaffirming Full Year 2026 Financial Guidance
Reaffirming Full Year 2026 Financial Guidance1 15 1. Excludes risks that are not yet known and/or quantifiable and related activities. Includes effects identified from licensing arrangements, collaborations and Merger & Acquisitions (“M&A”) transactions to the extent disclosed. The guidance is based
Slide 16: Capital Transactions During Full Year 2025 and First Quarter 2026
Capital Transactions During Full Year 2025 and First Quarter 2026 16 Use of ADSs1 held in treasury Period Number of issued ADSs Percentage of share capital2 Issue price Volume3 Biotheus Founder SBP Program January 2025 421,818 0.16% €116.58 €49.2 million ESOP 2018 Settlement March to December 2025 2
Slide 17: Capital Transactions During Full Year 2025 and First Quarter 2026
Capital Transactions During Full Year 2025 and First Quarter 2026 17 1. American Depositary Share (ADS), each representing one ordinary share. 2. The "percentage of share capital" ratio is calculated based on the shares issued as of March 31, 2026 (259,027,487). 3. Numbers have been rounded. Use of
Slide 18: Focused Capital Allocation Strategy for Sustainable Value Creation
Focused Capital Allocation Strategy for Sustainable Value Creation 18 1. Expected savings relative to BioNTech's 2025 cost base and CureVac's 2026 budget; do not reflect partially offsetting costs for CDMO use or transfer to other sites; and exclude exit costs, which will be recorded as incurred. Fo
Slide 19: Advanced Strategy, Matured Pipeline and De-risked Development Drive Oncology Execution
19 Advanced Strategy, Matured Pipeline and De-risked Development Drive Oncology Execution at Scale and Speed Diversified Multi- Product Company Progress key programs into pivotal stage, leverage partnership with BMS, fortified balance sheet to fund our pipeline Advance combination therapy studies, a
Slide 20: Thank you
__ Thank you
Slide 21: Reconciliation of IFRS to Adjusted Results – Q1 2026 & 2025
Reconciliation of IFRS to Adjusted Results – Q1 2026 & 2025 Financial Results In € millions except per share data1 Q1 2026 (unaudited) Q1 2025 (unaudited) IFRS Results Non-IFRS Adjustments Adjusted Results2 IFRS Results Non-IFRS Adjustments Adjusted Results2 Revenues 118 - 118 183 - 183 Cost of sale
Slide 22: Abbreviations
22 n L nth line DNA Desoxyribonucleic acid (sq) NSCLC (squamous) Non-small cell lung cancer ADC Antibody-drug conjugate EGFR Epidermal growth factor receptor P&L Profit and loss statement adj. Adjuvant ESOP Employee stock ownership plan PD-L1 Programmed cell death protein ligand 1 ADS American Depos